Genaissance partners INC Research to provide developmental support

As part of a plan to expand the market opportunities for its current pharmacogenetics service offering, Genaissance selected INC Research as its first contract research organization partner. Genaissance’s technology has been utilized by more than two-thirds of the top 20 pharmaceutical companies in support of over 550 clinical trials.

“Our clinical services business provides customers a turn-key means of adding world-class pharmacogenetic technology to their drug development programs, while at the same time eliminating capital investment and learning curves for the organization,” said Kevin Rakin, president and CEO of Genaissance.

Genaissance’s pharmacogenetic services span the entire drug development process and range from strategy formulation, to logistical management of samples and data, to identification of biomarkers of drug response. Laboratory services include sample management, DNA extraction and purification, DNA and tissue storage and banking, and genotyping and sequencing on multiple platforms.

“By utilizing the pharmacogenetic expertise represented by Genaissance, the potential benefit to our customers is improvement in the process of drug discovery, development and regulation,” stated Jim Ogle, CEO of INC Research. “INC Research is pleased to collaborate with Genaissance to provide further enhancements to our full service offering.”